Core Viewpoint - Meikang Bio (300439.SZ) reported its Q3 2025 results, highlighting a slight increase in institutional ownership and changes in public fund holdings [1] Institutional Investors - As of October 28, 2025, two institutional investors disclosed holdings in Meikang Bio A-shares, totaling 41.41 million shares, which represents 10.78% of the total share capital [1] - The institutional ownership increased by 0.03 percentage points compared to the previous quarter [1] Public Funds - One public fund, the Medical Device ETF, increased its holdings, contributing to a rise of 0.21% in ownership [1] - A total of 33 public funds did not disclose their holdings in this period, including notable funds such as E Fund CSI Wind Bio-Tech Index (LOF) A and others [1]

Group 1 - Zhejiang Lino (300838.SZ) released its Q3 2025 report on October 28, 2025, indicating that as of October 27, 2025, four institutional investors disclosed holding a total of 4.9783 million A-shares, accounting for 3.61% of the total share capital [1] - The institutional holding ratio decreased by 0.92 percentage points compared to the previous quarter [1] - Among public funds, one fund, CITIC Prudential Multi-Strategy Mixed (LOF) A, increased its holdings by 0.15% compared to the previous period [1] Group 2 - A total of 31 public funds that did not disclose their holdings in the current period were noted, including notable funds such as Nuon Multi-Strategy Mixed A and Jianxin Flexible Allocation Mixed A [1] - In terms of foreign investment, Barclays Bank PLC was noted as an external institution that did not disclose its holdings in the current period [2]